Skip to content
Search

Latest Stories

Follow Us:
Top Stories

Dark magic: Drug companies and the art of deception

Dark magic: Drug companies and the art of deception
Getty Images

Pearl is a clinical professor of plastic surgery at the Stanford University School of Medicine and is on the faculty of the Stanford Graduate School of Business. He is a former CEO of The Permanente Medical Group.

Magicians know the key to a convincing trick is misdirection.


They instruct you to follow the left hand so that you’ll ignore the right, which is subtly palming a ball or pulling an ace from the sleeve. The art of the illusion hinges on the magician’s ability to divert attention from where the real action is happening. And, therefore, every illusion conceals the truth.

Similarly, the U.S. biopharmaceutical industry has relied on subtle forms of misdirection in response to increased scrutiny from Congress, the Biden administration and health policy experts.

Here are three illusions drug companies have crafted to maintain massive profitability:

Illusion No. 1: A Death-Defying Feat

Drug research and development (R&D) has, for decades, gifted humanity with medical wonders: antibiotics, statins, cancer therapies and HIV/AIDS treatments.

In the 21st century, however, drug innovation has slowed while pharma companies have made exorbitant pricing a key business strategy. Over the past 18 years, biopharma companies have earned an average gross profit margin of 77%. Last year, the five largest pharma firms generated more than $81.9 billion in profits.

To combat runaway drug prices, Congress passed the Inflation Reduction Act last year, allowing the U.S. government to negotiate prices for a limited number of expensive medications starting in 2026.

The pharmaceutical sector immediately filed lawsuits. In public remarks, drug spokespeople have created the illusion that any reduction in drug-industry profits will destroy R&D innovation and harm millions of patients.

The Hidden Truth

Hidden in this illusion are three facts drug companies don’t want Americans to know. Combined, these truths tell a different story about pharmaceutical research and development.

First, an overwhelming percentage of drug prices gets channeled into corporate profits and administrative costs, not R&D. In fact, a report during the height of the pandemic found that 7 in 10 major drug companies spent more on marketing and sales than R&D.

Second, research concludes that price constraints would minimally impact drug discovery. The Congressional Budget Office estimates that reducing the pharmaceutical revenues would result in just one less drug over the next decade and a total of 1% fewer medications over the next 30 years.

The third and most pernicious part of the illusion is getting people to ignore how many Americans are harmed by the unaffordability of life-essential medications. One example is insulin prices, which have tripled over the past decade. As a result, researchers from Yale found 25% of children with type 1 diabetes are given lower doses by their parents than their physicians recommend.

Nearly 1 in 4 Americans on prescription drugs now report difficulty affording their medications. That is the hidden truth. Exorbitant Rx prices hurt and kill far more Americans than the supposed loss of R&D ever would.

Illusion No. 2: The Statue Of Liberty Trick

Once Americans buy into the illusion that exorbitant drug prices are necessary to save lives, pharmaceutical companies move on to the next sleight of hand.

It goes like this: The United States, alone, must shoulder the enormous burden of drug prices.

Right now, Americans pay 2.4 to 3.4 times more for medications than in peer nations.

Much of the disparity in spending dates back to 2003 when Congress passed a law prohibiting the U.S. government from negotiating drug prices. And without any pricing regulations in place, domestic drug companies have pushed the boundaries ever higher. Over the past two years, nearly half of FDA approved medications have debuted above $150,000 with several topping $1 million per patient.

Outside of the United States, excessively high drug prices are a rarity.

Ozempic exemplifies the problem. This diabetes drug helps people lose significant weight while also avoiding heart attacks. A month’s supply of it costs $936 in the United States. In Japan, it sells for $169. It’s just $93 in the UK, $87 in Australia and $83 France.

Each of these countries has instituted drug-pricing controls and caps on drugmaker profits. If our nation adopted the same regulations, we could prescribe Ozempic to every overweight and obese American, and affordably solve the obesity epidemic. But under current retail pricing, doing so would increase drug spending $1.5 trillion per year, raising overall healthcare costs by 25%.

The Hidden Truth

The illusion here is that drug prices in other wealthy nations are non-negotiable.

But of course, that’s not accurate. American drug companies could play hardball with peer countries, refusing to sell their medications unless a more equitable pricing structure can be reached.

But why bother when you can simply stick Americans with the bill?

Illusion No. 3: What’s In Your Pocket?

When it comes to purchasing prescription drugs, there are two prices. There’s the very high retail price drug companies charge and the much-smaller amount insured patients pay when they pick up their medications (the out-of-pocket expense).

Since out-of-pockets are only small fraction of the total drug expense, drug companies would like Americans to concentrate on those dollars. But that requires people to assume the rest of the money—paid by the government or private businesses—is free.

The Hidden Truth

The reality is that workers and taxpayers wind up paying the price for expensive medications in two ways:

1. Workers earn less pay as benefit costs increase. That’s because employers treat wages and healthcare benefits as a single expense. As medical costs soar, raises disappear and salaries stagnate.

2. Taxpayers either pay more or get less. When medical costs rise, the government must either raise taxes or cut programs, including school funding and public safety.

Deception and misdirection can be sources of wonder at magic shows. But illusions in healthcare prove to be disturbing, dangerous and deadly.


Read More

White marble exterior of the United States Capitol, often called the Capitol Building, is the home of the United States Congress and the seat of the legislative branch of the U.S. federal government

This week's congressional agenda includes anti-fraud legislation, ICE funding, FISA Section 702 renewal debates, and major committee hearings.

Richard Sharrocks / Getty Images

Fraud, Funding, and FISA

Fraud

This week in the House is Fraud Week based on the large number of bills likely to receive a vote that in some way are intended to decrease or eliminate many different kinds of fraud. Example bills up for a vote include:

Funding

One bill will likely become law this week if it passes the House:

Keep ReadingShow less
Anti-gerrymandering sign

Florida's new congressional map, the Supreme Court's Callais decision, and challenges to voting rights protections raise urgent questions about redistricting, representation, and democratic accountability.

Bill Clark/Getty Images

Florida’s New Map and the Shrinking Window for Accountability

When the Lines Began Moving Faster Than the Law

On May 4, Governor Ron DeSantis signed Florida’s new congressional map into law. The Legislature had passed it five days earlier, 83 to 28 in the House and 21 to 17 in the Senate. The map redraws four districts in ways that election analysts project would shift them from competitive or Democratic-leaning to safe Republican, potentially expanding a delegation Republicans already control 20 to 8.

The same day the Legislature voted, the Supreme Court decided Louisiana v. Callais. The Court ruled 6 to 3 that Louisiana’s majority-minority district could not survive Equal Protection scrutiny under the standards applied by the majority. In her dissent, Justice Elena Kagan wrote that the ruling “renders Section 2 all but a dead letter” in redistricting.

Keep ReadingShow less
How America Redraws Belonging
woman with US American flag on her shoulders
Photo by Josh Johnson on Unsplash

How America Redraws Belonging

America has always redrawn the boundaries of belonging.

What counts as "us" has never been fixed. The lines have shifted over time, sometimes slowly and sometimes painfully, but they have always shifted.

Keep ReadingShow less
Illustration of Sojourner Truth after a Photograph

Portrait of Sojourner Truth (ca. 1797-1883), leader of the Underground Railroad.

Bettmann / Getty Images

Sojourner’s Truth

As the United States prepares to mark the 250th anniversary of its founding later this summer, there will be extensive celebration and reflection about our democracy and the values it embodies. But the 250th is not the only anniversary that should capture our attention. Indeed, our nation’s story is an evolution of moments built over time.

One of these building blocks occurred 175 years ago, in 1851, during the Women’s Convention in Akron, Ohio. There, on May 29th, Sojourner Truth delivered a legendary speech that called on attendees to reject the racial and gender biases used to limit her place in society and to defy a status quo that devalued her as a Black woman and treated her as invisible and expendable. Her speech is worthy of reflection today because it reveals an important story about how different people experience our democracy — and that story should inform how we build a more inclusive vision for our future.

Keep ReadingShow less